Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flecainide dose-response relations in stable ventricular arrhythmias.

R L Woosley, L A Siddoway, H J Duff

    The American Journal of Cardiology
    |February 27, 1984
    PubMed
    Summary

    Flecainide acetate effectively suppressed ventricular arrhythmias in most patients, with optimal results often seen at lower daily doses. Long-term therapy demonstrated sustained efficacy and safety without chronic toxicity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes.

    Annales d'endocrinologie·2020
    Same author

    New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine.

    Clinical pharmacology and therapeutics·2017
    Same author

    The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

    Clinical pharmacology and therapeutics·2017
    Same author

    Pharmacogenetic Implementation Lessons From the "Real World".

    Clinical pharmacology and therapeutics·2016
    Same author

    A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.

    Clinical pharmacology and therapeutics·2016
    Same author

    Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network.

    Clinical pharmacology and therapeutics·2016

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • High-frequency ventricular arrhythmias pose a significant clinical challenge.
    • Identifying effective and safe antiarrhythmic agents is crucial for patient management.

    Purpose of the Study:

    • To evaluate the efficacy and safety of flecainide acetate in patients with stable, high-frequency ventricular arrhythmias.
    • To determine the optimal dosage range for flecainide acetate therapy.

    Main Methods:

    • A placebo-controlled, dose-ranging study involving 35 patients across three centers.
    • A 3-stage protocol including placebo baseline, escalating oral dosages (100-300 mg twice daily), and reinstituted placebo.
    • Post-discharge evaluation at 7 and 14 days to assess sustained efficacy.

    Main Results:

    Related Experiment Videos

    • Significant suppression of ventricular premature complexes (VPCs) (>80%) and complex VPCs (>95%) in 30 out of 35 patients.
    • Arrhythmia suppression achieved in 73% of patients at dosages of 100-200 mg twice daily.
    • Mild side effects reported in 46% of patients, often manageable with dosage adjustments.
    • Sustained efficacy for 2 years in 24 out of 29 patients without chronic toxicity.

    Conclusions:

    • Flecainide acetate is an effective antiarrhythmic agent for stable ventricular arrhythmias.
    • A narrow range of effective dosages exists, with many patients responding to 100-200 mg twice daily.
    • Long-term treatment is well-tolerated, supporting its use in managing ventricular arrhythmias.